Notice to Readers
Revised Dosing Regimen for Malaria Prophylaxis with Mefloquine
A U.S. interagency group on malaria prevention has recently reviewed documented experience on the effectiveness and tolerance of mefloquine (Lariam((R))) for malaria prophylaxis. Based on this review, the group has proposed a change in the dosing regimen for malaria prophylaxis with mefloquine. Consequently, CDC has revised the dosing recommendations for mefloquine use. The new regimen consists of a single dose of mefloquine to be taken weekly, starting 1 week before travel. Prophylaxis should be continued weekly during travel in malarious areas and for 4 weeks after a person leaves such areas.
This notice updates the information in the following
publications:
CDC. Recommendations for the prevention of malaria among travelers. MMWR 1990;39(no. RR-3):4.
CDC. Health information for international travel, 1990. Atlanta: US Department of Health and Human Services, Public Health Service, 1990:98; DHHS publication no. (CDC)90-8280. Detailed recommendations for the prevention of malaria may be obtained 24 hours a day by calling the CDC Malaria Hotline at (404) 332-4555.
Information about the availability of mefloquine can be obtained from the manufacturer at (800) 526-6367. Reported by: Malaria Br, Div of Parasitic Diseases, Center for Infectious Diseases, CDC.
Disclaimer
All MMWR HTML documents published before January 1993 are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.
